Novo Nordisk's Strategic Shift Amidst U.S. Pricing Pressure

Novo Nordisk has hired U.S. pharmaceutical executive Greg Miley as its global head of corporate affairs. This move comes as the company faces increasing pressure from U.S. President Donald Trump over drug pricing. Miley previously held a senior position at AbbVie and shared his appointment news on LinkedIn.

Novo Nordisk has announced the appointment of Greg Miley, a seasoned U.S. pharmaceutical executive, as its new global head of corporate affairs.

This strategic hiring decision comes as the company navigates growing pressure from U.S. President Donald Trump, particularly concerning drug pricing strategies.

Miley, who recently held a senior vice presidency in government affairs at AbbVie, confirmed his new role on LinkedIn, a declaration that was later corroborated by Novo Nordisk to Reuters.

(With inputs from agencies.)